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Introduction 
Central nervous system (CNS) disorders account for 12% of deaths worldwide, and those 
who survive are reported to have a poor quality of life. The impairment of neurological 
functions in CNS disorders is the result of compromised intrinsic neuroprotective, 
neurotrophic and neurogenic equilibrium, leading to severe damage to the structural and 
functional integrity of the brain. Restoring CNS homeostasis after an injury or a disease is a 
major challenge. Neurotrophins or neurotrophic factors, like Brain-Derived Neurotrophic 
Factor (BDNF) and Glia-Derived Neurotrophic Factor (GDNF), have shown promising 
outcomes in these restoration processes. Though the approach of exogenously administering 
neurotrophins seems to be a potent therapeutic alternative in treating neurological disorders, 
they have so far failed to cross preclinical or clinical stages because of limitations owing to 
its proteinaceous nature, stability in the system (bioavailability), blood-brain barrier 
permeability and non-selectivity. Hence, there is a dearth of therapeutic interventions that can 
slow down neurodegeneration and help in the repair and regeneration of neurons in the 
affected brain circuitry. These suboptimal pharmacological properties of neurotrophins can 
be overcome by using small molecules which mimic neurotrophins or which can augment the 
expression of neurotrophins. This has galvanized research into new compounds, including 
natural products, that mimic neurotrophic factors or act as neuromodulators to accelerate 
neuritogenesis and result in neuroprotection.  
Based on all these observations, in the present work, we evaluated the in vitro and  in 
vivo neuroactive properties of few compounds which are lichen-derived and few synthetic 
ones like - Fellutamide B fragments and HDAC inhibitor. 
Statement of problem 
Neurotrophic small molecules have been shown to ameliorate the pathophysiology of 
neurodegenerative and psychiatric disorders in preclinical rodent models. Nevertheless, there 
is a dearth of therapeutics available in clinics to promote neuroprotection, neurite 
regeneration and neurogenesis. Small molecules from natural resources and synthetic 
approach have shown potential in reversing the impaired neurotrophic milieu. Hence we 
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followed our interest to assess the neuroactive potential of small molecules from natural 
resources (Lichen derived compounds) and synthetic compounds ( Fellutamide B fragments) 
in in vitro neurotrophic and neurogenic assays. In addition, the promising compounds were 
taken to the next level, i.e. pre-clinical studies, for their in vivo neuroactive therapeutic 
potential in chronic stress induced neuropsychiatric models in zebrafish.  
Objectives of the study 
1. Role of Lichen derived compound on central nervous system functions 
2. Role of Fellutamide B fragments on central nervous system functions. 
3. Role of novel HDAC inhibitors on central nervous system functions 
Methodologies Used and Sample Results 
We considered twelve lichen-derived metabolites as possible pharmacological agents for 
diverse neurodegenerative and neuropsychiatric disorders. The in vitro neurotrophic activity 
of these agents or compounds was assessed first in in vitro assays using Neuro2A cells. We 
observed that out of twelve only four lichen compounds (atranorin, perlatolic acid, physodic 
acid and usnic acid) exhibited potent neurotrophic activity and their neurotrophic potential 
was similar to that of a known neurotrophin NGF. In addition, we found that one of the four, 
perlatolic acid, exhibited more neurotrophicity than the well-studied neuroactive natural 
compound, resveratrol.  Except for Usnic acid, all other neurotrophic compounds (atranorin, 
physodic acid and perlatolic acid) have shown no change in the viability of cells at the 
optimum neurite outgrowth concentration. The active lichen compounds identified in our 
study elicited the upregulation of neurotrophins BDNF and NGF to a degree comparable to 
that of NGF positive control. We also uncovered the underlying molecular signaling involved 
in perlatolic acid-induced neurotrophicity, by assessing action on the MAPK-ERK and PI3K-
AKT pathways. Unlike some of neurotrophic compounds, perlatolic acid did not show 
enhancement in the level of pERK and pAKT. These results prompted us evaluated the levels 
of histone modifications (acetyl H3 and acetyl H4) in perlatolic acid-treated Neuro2A cells. 
The results showed increase in acetyl H3 and H4 levels, compared to the vehicle treatment, 
following perlatolic acid treatment; similar to what was shown in cells treated with the 
classical HDAC inhibitor sodium butyrate (the positive control). In addition to the potential 
neurotrophic action, perlatolic acid also exhibited good proneurogenic activity in ex vivo 
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neurosphere cultures at 0.5 µM. The compound perlatolic acid is taken for assessing their in 
vivo antidepressant-like activity in Zebrafish chronic stress-induced depression model. The 
anxiolytic and antidepressant-like activity of compounds were evaluated with Novel tank test 
and social interaction test. Compound perlatolic acid has shown a trend in its mood elevating 
effect. These results and other findings warrant further exploration of the neuroactive 
pharmacological properties of lichen compounds in higher in vivo model systems such as 
rodents.  
Fellutamide B has been reported to have anti-tuberculosis and in vitro cytotoxic activity. 
In addition, Fellutamide B has been also observed to have NGF-induced neurotrophic 
activity. In this direction, researchers suggested  Fellutamide B scaffold and its simplified 
analogues to be promising in the development of neurotrophic small molecule therapeutics to 
treat CNS disorders. We evaluated all four fragments of Fellutamide B ( A, B, C and D) for 
assessing their in vitro neurotrophic acitivity and observed that all the four compounds have 
good potential for the neurite outgrowth, similar to that of NGF, and the dose at which the 
compounds showed optimum neurotrophic effect did not have any effect on the viability of 
Neuro2Acells. Furthermore, all the compounds have shown potential for the pro neurogenic 
activity in ex vivo neurosphere assay and compound C also showed the neurogenic activity in 
zebrafish embryos. Additionally, these compounds have shown the increase in histone 
acetylation at the dose which was pro neurogenic. 
On summarizing the results obtained, compound #A and #C were selected for taking 
these further to zebrafish chronic stress model, to evaluate their anxiolytic and antidepressant 
activities. Comp#A and #C have shown good anxiolytic and antidepressant like activity in 
the Novel tank test and social interaction test. In addition, the compounds have effectively 
induced the levels of neurtrophin (BDNF) in zebrafish brain. 
Histone deacetylase inhibitors (HDACi) have emerged as fascinating epigenetic 
therapeutics to target cancer and have been in clinical trial for diverse CNS disorders. 
However, except for the HDACi SAHA (Suberoylanilide hydroxamic acid), the other 
classical HDACi failed to reach clinics for their side effects including toxicity, compromised 
potency and selectivity. Vorinostat (SAHA that reached clinics to treat cutaneous T cell 
lymphoma) too has cardiotoxicity and nephrotoxicity. So, we started to screen the library of 
small molecules based on Tubacin (HDAC6i) and SAHA scaffolds. Novel HDACi were 
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evaluated for PAN HDAC inhibition. Compounds with more/equal PAN HDACi were 
considered for the in vitro neurite outgrowth. Furthermore, these compounds were also 
screened for antidepressant activity in zebrafish chronic stress-induced depression and 
anxiety model. The compound (51c) shows promising anti-anxiety and antidepressant 
activity in Novel tank test and social interaction test. The zebrafish brain also showed the 
enhanced level of BDNF when treated with the compound having antidepressant activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
